Z103

Zolpidem

≥98% (HPLC), solid, benzodiazepine receptor agonist

• Synonyme(s) : N,N,6-Trimethyl-2-(4-methylphenyl)-imidazo[1,2-a]pyridine-3-acetamide
• Formule empirique (notation de Hill) : C₁₉H₂₁N₃O
• Numéro CAS: 82626-48-0
• Poids moléculaire : 307.39
• UNSPSC Code: 12352200
• PubChem Substance ID: 24902172
• NACRES: NA.77
• MDL number: MFCD00153885
• Assay: ≥98% (HPLC)
• Form: solid

Propriétés

• Nom du produit: Zolpidem, ≥98% (HPLC), solid
• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: solid
• drug control: USDEA Schedule IV; Home Office Schedule 4.1; psychotrope (France); kontrollierte Droge in Deutschland; regulated under CDSA - not available from Sigma-Aldrich Canada; psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal); Pszichotróp anyag / Psychotropic Substance (Hungary), 78/2022. (XII. 28.) BM rendelet, kontrollierte Droge in Deutschland
• color: white
• solubility: 45% (w/v) aq 2-hydroxypropyl-β-cyclodextrin: 0.3 mg/mL, DMSO: >10 mg/mL, ethanol: 50 mg/mL, methanol: 50 mg/mL, H₂O: insoluble, dilute aqueous base: insoluble
• originator: Sanofi Aventis
• SMILES string: CC1=CN2C(C=C1)=NC(C3=CC=C(C)C=C3)=C2CC(N(C)C)=O
• InChI: 1S/C19H21N3O/c1-13-5-8-15(9-6-13)19-16(11-18(23)21(3)4)22-12-14(2)7-10-17(22)20-19/h5-10,12H,11H2,1-4H3
• InChI key: ZAFYATHCZYHLPB-UHFFFAOYSA-N
• Gene Information: human ... GABRA1(2554), GABRA2(2555), GABRA3(2556), GABRA5(2558), GABRA6(2559), GABRB1(2560), GABRG2(2566) ; rat ... Gabra1(29705), Gabra2(29706), Gabra5(29707), Tspo(24230)

Description

Biochem/physiol Actions

Potent and selective agonist for the benzodiazepine receptor associated with the GABA_A receptor; hypnotic.

Features and Benefits

This compound is a featured product for Neuroscience research. Click here to discover more featured Neuroscience products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.

This compound is featured on the GABAA Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

This compound was developed by Sanofi Aventis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Legal Information

German
Dieses Produkt fällt unter das Betäubungsmittelgesetz (BtMG). Für eine Bestellung dieses Produktes ist eine Erlaubnis nach § 3 BtMG zwingend erforderlich, es sei denn, es greift eine Ausnahme von der Erlaubnispflicht nach § 4 oder § 26 BtMG.

English
This product is subject to the German Narcotics Act. A permit under Section 3 of the German Narcotics Act is mandatory for ordering this product unless an exemption from the permit requirement under Section 4 or Section 26 of the German Narcotics Act applies.

Informations sur la sécurité

• Pictogrammes: GHS07,GHS09
• Mot-clé: Warning
• Codes de danger: H302,H336,H411
• Mentions de précaution: P261 - P264 - P271 - P273 - P301 + P312 - P304 + P340 + P312
• Hazard Classifications: Acute Tox. 4 Oral - Aquatic Chronic 2 - STOT SE 3
• Organes cibles: Central nervous system
• Classe de stockage: 11 - Combustible Solids
• Que se passe-t-il ?: WGK 3
• Point d'éclair (°F): Not applicable
• Point d'éclair (°C): Not applicable
• EPI (équipement de protection individuelle): Eyeshields, Gloves, type N95 (US)